ImYoo is a Public Benefit Corporation based in South San Francisco, CA, dedicated to leveraging breakthrough multi-omic tools to uncover individuals' immune dynamics. With a patient-driven biodiscovery ecosystem, ImYoo conducts patient-centric immune discovery studies by enabling patients to self-collect small volumes of blood at home for high-resolution single-cell genomics assays, aiming to predict kidney transplant rejection and enable precision diagnosis and therapies.
By capturing relevant events as they happen and understanding the complexities of diseases, ImYoo strives to advance medical research and technology, offering opportunities for patients, clinicians, researchers, funders, and other stakeholders to participate in their studies and stay updated on their groundbreaking work.
Generated from the website